Cancer
Permanent URI for this collectionhttps://hdl.handle.net/20.500.12503/21728
Browse
Browsing Cancer by Author "Dong, Xiaowei"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Development of Curcumin Loaded Nanoparticles and Evaluation of Antitumor Effects on Prostate Cancer Cell Lines(2015-03) Tanaudommongkon, Irin; Tanaudommongkon, Asama; Prathipati, Priyanka; Dong, XiaoweiPurpose (a): Curcumin (CUR) is a low molecular weight, lipophilic, yellow polyphenolic compound of Indian spice turmeric. In recent years, CUR has been shown as an effective antiproliferative agent in many cancer cell lines such as breast cancer and prostate cancer. Due to low water solubility and instability, the formulation of CUR is challenging and this prevents the usage of CUR in anticancer application. Lipid based nanoparticle (NP) delivery system is a promising approach to formulate CUR, in terms of its abilities in formulating lipophilic drugs, improving the drug’s pharmacokinetics and biodistribution, and reducing drug toxicity. The main objective of this study is to develop CUR NPs by optimizing NPs with varying compositions of lipids and surfactants. Methods (b): The preparation of nanoparticles was performed by a warm o/w microemulsion system. The drug loading and entrapment efficiency of CUR NPs were measured by using HPLC. Particle size was determined by using photon correlation spectroscopy. The in-vitro cytotoxicity of CUR NPs were performed by using MTT assays in PC3 and DU145 prostate cancer cell lines. Results (c): We were able to load CUR into the NPs made of Migloyl 812 and TPGS (1:1, w/w). Particle size was less than 150 nm with polydispersity index95% and drug loading was >5%. CUR NPs were stable for up to 5 months at 4°C and up to 96 hours at 37°C in PBS buffer (pH 7.4) without significant changes in particle sizes. For both sensitive and resistant PC3 and DU145 cell lines, CUR NPs significantly reduced IC50 values over free drug. Conclusions (d): We successfully prepare CUR NPs using lipid-based NPs. CUR NPs significantly improved cytotoxicity of CUR in sensitive and resistant prostate cancer cells compared to free CUR.Item Development of Docetaxel-Loaded Lipid Nanoparticles for Prostate Cancer Treatment(2015-03) Tanaudommongkon, Asama; Tanaudommongkon, Irin; Prathipati, Priyanka; Dong, XiaoweiPurpose: Using docetaxel-based therapy (DTX) for treatment for men with castration-resistant prostate cancer (CRPC) showed efficacy on improving overall survival. Despite this promising outcome, toxicities and adverse events of DTX limit the dose and dosage frequency. Moreover, patients develop DTX resistance eventually. Nanoparticle (NP) drug delivery systems offer alternative therapeutic options for the treatment of prostate cancer. The goal of this study is to develop novel DTX NPs to treat CRPC. Method: Lipid and surfactant were selected using the solubility test. DTX NPs were prepared by an emulsion method. The NPs were characterized in terms of particle size, polydispersity index, short-term stability, drug loading, drug entrapment efficiency, in vitro release study, and cytotoxicity studies in DU145 and PC3 prostate cancer cell lines. Results: DTX NPs were prepared using a proportionally amount of Migloyl 812 as the oil phase and TPGS as the surfactant phase. All tested NPs had particle size less than 150 nm with polydispersity index of less than 0.35. DTX NPs were physically stable at 4°C over five months and in PBS at 37°C over 96 hours as measured by particle size. DTX NPs had the drug entrapment efficiency over 90% with drug loading over 5%. The cytotoxicity studies demonstrated that there was no significant difference in IC50 values for the sensitive PC3 and DU145 cells between DTX NPs and free DTX. For the resistant PC3 and DU145 cells, DTX NPs significantly reduced IC50 values compared to free DTX. Conclusions: DTX NPs were successfully prepared and characterized. DTX NPs showed comparable cytotoxicity in sensitive prostate cancer cells, and superior cytotoxicity in resistant prostate cancer cells compared to free DTX. Therefore, DTX NPs have the potential to treat CRPC and overcome drug resistance.